PRESS RELEASE : Immunic, Inc. to Participate in Industry and Investor Conferences in June

DGAP-News: Immunic, Inc. / Key word(s): Conference 
Immunic, Inc. to Participate in Industry and Investor Conferences in June 
2021-06-10 / 12:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Immunic, Inc. to Participate in Industry and Investor Conferences in June 
NEW YORK, June 10, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a 
pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today 
announced participation in the following industry and investor conferences in June: 
- June 14-18: BIO Digital (formerly BIO International Convention). Members of the company's business development team 
will host one-on-one partnering meetings during the conference. To schedule a meeting, please use the BIO Digital 
partnering portal at: www.bio.org/events/bio-digital/partnering. 
- June 16-17: JMP Securities Life Science Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of 
Immunic, will participate in a fireside chat on Thursday, June 17, at 11:30 am ET. A live audio webcast of the 
presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/ 
events-and-presentations. An archived replay will be available on the company's website for a period of 90 days. 
About Immunic, Inc. 
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology 
therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small 
molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular 
metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is 
currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and 
primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?t, is targeted for 
development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier 
function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please 
visit: www.imux.com. 
Cautionary Statement Regarding Forward-Looking Statements 
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes 
of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than 
statements of historical facts, included in this press release regarding strategy, future operations, future financial 
position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking 
statements. Examples of such statements include, but are not limited to, statements relating to management's 
participation in industry and investor conferences. Immunic may not actually achieve the plans, carry out the 
intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place 
undue reliance on these forward-looking statements. Such statements are based on management's current expectations and 
involve risks and uncertainties. Actual results and performance could differ materially from those projected in the 
forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and 
uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future 
liabilities and business operations, the availability of sufficient resources to meet business objectives and 
operational requirements, the fact that the results of earlier studies and trials may not be predictive of future 
clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks 
related to the drug development and the regulatory approval process and the impact of competitive products and 
technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in 
the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 
31, 2020, filed with the SEC on February 26, 2021, and in the company's subsequent filings with the Securities and 
Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any 
forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent 
or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date 
on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on 
any or all the contents of this press release. 
Contact Information 
Immunic, Inc. 
Jessica Breu 
Head of Investor Relations and Communications 
[phone] 
[e-mail] 
US IR Contact 
Rx Communications Group 
Paula Schwartz 
[phone] 
[e-mail] 
US Media Contact 
KOGS Communication 
Edna Kaplan 
[phone] 
[e-mail] 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-10 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1206237 2021-06-10

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1206237&application_name=news

(END) Dow Jones Newswires

June 10, 2021 06:30 ET (10:30 GMT)